The biosimilar SB4 produced response rates equivalent to those associated with etanercept (ETN; Enbrel, Amgen) in patients with severe rheumatoid arthritis (RA) whose disease was not controlled by ...

ZURICH (Reuters) - The U.S. Food and Drug Administration has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster Enbrel drug, the Swiss ...

Sandoz Group AG (OTC:SDZNY) (OTC:SDZXF) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ:AMGN) for extending and entrenching the dominant market position of its blockbuster ...

The rates of discontinuation due to inefficacy or adverse events for biosimilars and originators of etanercept and adalimumab were similar, according to an analysis of a prospective registry. The ...

Real-world data suggest anti-TNF biosimilars for juvenile idiopathic arthritis offer comparable efficacy and safety to their brand name counterparts. As high-cost originator biologics continue to ...

The Supreme Court declined to review a petition filed by Novartis’ Sandoz unit that challenged two of Amgen’s patents on its blockbuster rheumatoid arthritis drug, Enbrel, meaning there won’t be a ...

Sandoz has filed an antitrust lawsuit in the United States against Amgen, for extending and entrenching the dominant market position of its blockbuster medicine, Enbrel (etanercept). The drug was ...

No biosimilar producers have made use of an accelerated US approval pathway introduced in 2010, and now the first case has found against a biosimilar for Enbrel. George Yu and Jason Harp explain where ...

Discontinuation rates over 2 to 3 years of follow-up were 53.3% for originator products versus 33.4% for biosimilars, according to María Paz Martínez-Vidal, MD, PhD, of Hospital Universitario San Juan ...

(RTTNews) - Sandoz (SDZNY) has initiated an antitrust lawsuit in the United States against Amgen, Inc. (AMGN), accusing the company of maintaining its dominant market position for the blockbuster drug ...